# Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer

Source: [nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMc2610895?af=R&rss=currentIssue) · 2026-11-18 · Medicine
Page: https://themorning.science/story/enfortumab-vedotin-and-pembrolizumab-for-cisplatin-eligible-bladder-cancer-5e688ff80e2414bb
Kind: research · Impact: medium

## In brief

- A New England Journal of Medicine correspondence titled 'Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer' was published.
- It appears in Volume 395, Issue 20, pages 2073-2075, with an issue date of November 19, 2026.
- The provided source contains only the title and citation, so no trial results or methods are available here.

## Why it matters

The letter concerns combined enfortumab vedotin and pembrolizumab treatment for bladder cancer in patients who are eligible for cisplatin, a setting relevant to clinicians treating this disease. The source provided does not include its findings, so the practical implications cannot be assessed from it.

## Timeline

- 2026-11-19: Published in the New England Journal of Medicine, Volume 395, Issue 20, pages 2073-2075

## Coverage

- [Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer](https://www.nejm.org/doi/full/10.1056/NEJMc2610895?af=R&rss=currentIssue) — nejm.org, 2026-11-18

Tags: bladder cancer, oncology, immunotherapy, enfortumab vedotin, pembrolizumab

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
